Albireo Pharma, Inc. (ALBO)
Stock Price:
$24.83 USD
0.65 (2.69%)
Updated Aug 6, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
371.94M |
| Revenue (ttm) |
10.62M |
| Net Income (ttm) |
-81.52M |
| Shares Out |
14.98M |
| EPS (ttm) |
-5.98 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 6, 2020 |
| Last Price |
$24.83 |
| Previous Close |
$24.18 |
| Change ($) |
0.65 |
| Change (%) |
2.69% |
| Day's Open |
24.85 |
| Day's Range |
24.56 - 28.20 |
| Day's Volume |
226,334 |
| 52-Week Range |
11.26 - 31.50 |
More Stats
| Market Cap |
371.94M |
| Enterprise Value |
229.32M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
14.98M |
| Float |
11.75M |
| EPS (basic) |
-5.91 |
| EPS (diluted) |
-5.98 |
| FCF / Share |
-4.90 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
418,340 |
| Short Ratio |
4.69 |
| Short % of Float |
3.51% |
| Beta |
1.88 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
35.04 |
| PB Ratio |
3.73 |
| Revenue |
10.62M |
| Operating Income |
-78.25M |
| Net Income |
-81.52M |
| Free Cash Flow |
-73.40M |
| Net Cash |
142.62M |
| Net Cash / Share |
9.52 |
| Gross Margin |
90.78% |
| Operating Margin |
-737.18% |
| Profit Margin |
-722.90% |
| FCF Margin |
-691.46% |
| ROA |
-24.92% |
| ROE |
-68.99% |
| ROIC |
-12,568.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
7 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$51.25*
(106.40% upside)
Low
39.0
Current: $24.83
High
64.0
Target: 51.25
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 9.64 | 12.74 | - | 11.36 | 5.10 | - | - | - | - | - |
| Revenue Growth | -24.36% | 1273900% | -99.99% | 122.87% | - | - | - | - | - | - |
| Gross Profit | 9.64 | 12.74 | - | 11.36 | 5.10 | - | - | - | - | - |
| Operating Income | -61.11 | -37.89 | -24.58 | -12.29 | -4.73 | -19.26 | -20.59 | -19.30 | -23.22 | -37.16 |
| Net Income | -62.72 | -46.11 | -24.41 | -16.35 | -6.77 | -14.13 | -19.34 | -20.75 | -10.59 | -38.29 |
| Shares Outstanding | 12.44 | 11.70 | 7.82 | 1.24 | 0.27 | 0.71 | 0.52 | 0.36 | 0.26 | 0.20 |
| Earnings Per Share | -5.04 | -3.94 | -3.12 | -13.19 | -25.49 | -19.80 | -37.20 | -57.31 | -40.80 | -190.22 |
| Operating Cash Flow | -52.92 | -26.80 | -27.57 | -8.78 | -4.75 | -18.72 | -18.56 | -16.70 | -18.25 | -34.38 |
| Capital Expenditures | -0.54 | -0.05 | 4.31 | - | - | -0.05 | -0.12 | -0.06 | -0.19 | -0.29 |
| Free Cash Flow | -53.46 | -26.85 | -23.26 | -8.79 | -4.75 | -18.77 | -18.67 | -16.76 | -18.44 | -34.67 |
| Cash & Equivalents | 132 | 164 | 53.23 | 29.93 | 5.12 | 24.59 | 39.78 | 39.11 | 38.76 | 29.07 |
| Total Debt | - | - | - | 3.08 | 7.38 | - | - | - | - | - |
| Net Cash / Debt | 132 | 164 | 53.23 | 26.86 | -2.26 | 24.59 | 39.78 | 39.11 | 38.76 | 29.07 |
| Assets | 165 | 185 | 73.22 | 49.66 | 6.97 | 25.43 | 41.15 | 41.13 | 41.51 | 32.62 |
| Liabilities | 71.91 | 62.83 | 7.97 | 12.71 | 15.20 | 2.63 | 8.59 | 10.12 | 4.43 | 8.56 |
| Book Value | 93.16 | 123 | 65.25 | 36.95 | -8.74 | 22.80 | 32.56 | 31.02 | 37.08 | 24.06 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Albireo Pharma, Inc. |
| Country |
United States |
| Employees |
55 |
| CEO |
Ronald H. W. Cooper |
Stock Information
| Ticker Symbol |
ALBO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ALBO |
Description
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis; and A3384 for the treatment of gastrointestinal diseases. It has a license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.